Display options
Cite
Heeke S, Benzaquen J, Long-Mira E, et al. In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients. Cancers (Basel). 2019;11(9)doi: 10.3390/cancers11091271.
Heeke, S., Benzaquen, J., Long-Mira, E., Audelan, B., Lespinet, V., Bordone, O., Lalvée, S., Zahaf, K., Poudenx, M., Humbert, O., Montaudié, H., Dugourd, P. M., Chassang, M., Passeron, T., Delingette, H., Marquette, C. H., Hofman, V., Stenzinger, A., Ilié, M., & Hofman, P. (2019). In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients. Cancers, 11(9), . https://doi.org/10.3390/cancers11091271
Heeke, Simon, et al. "In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients." Cancers vol. 11,9 (2019). doi: https://doi.org/10.3390/cancers11091271
Heeke S, Benzaquen J, Long-Mira E, Audelan B, Lespinet V, Bordone O, Lalvée S, Zahaf K, Poudenx M, Humbert O, Montaudié H, Dugourd PM, Chassang M, Passeron T, Delingette H, Marquette CH, Hofman V, Stenzinger A, Ilié M, Hofman P. In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients. Cancers (Basel). 2019 Aug 29;11(9). doi: 10.3390/cancers11091271. PMID: 31470674; PMCID: PMC6769455.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2019 Aug 29;11(9). doi: 10.3390/cancers11091271.

In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients.

Cancers

Simon Heeke, Jonathan Benzaquen, Elodie Long-Mira, Benoit Audelan, Virginie Lespinet, Olivier Bordone, Salomé Lalvée, Katia Zahaf, Michel Poudenx, Olivier Humbert, Henri Montaudié, Pierre-Michel Dugourd, Madleen Chassang, Thierry Passeron, Hervé Delingette, Charles-Hugo Marquette, Véronique Hofman, Albrecht Stenzinger, Marius Ilié, Paul Hofman

Affiliations

  1. Université Côte d'Azur, 06000 Nice, France.
  2. Team 4, Institute for Research on Cancer and Aging Nice (IRCAN), Institut de la Santé et de le Recherche Médicale (INSERM) U1081/CNRS 7284, 06107 Nice, France.
  3. Laboratory of Clinical and Experimental Pathology, Biobank BB-0033-00025, Centre Hospitalier Universitaire de Nice, 06000 Nice, France.
  4. FHU OncoAge, Pasteur Hospital, 06000 Nice, France.
  5. Department of Pulmonology and Thoracic Oncology, Centre Hospitalier Universitaire de Nice, 06000 Nice, France.
  6. Epione Team, Inria, Sophia Antipolis, 06902 Valbonne, France.
  7. Department of Oncology, Antoine Lacassagne Comprehensive Cancer Center, 06200 Nice, France.
  8. Department of Nuclear Medicine, Antoine Lacassagne Comprehensive Cancer Center, 06200 Nice, France.
  9. Department of Dermatology, Archet II Hospital, Centre Hospitalier Universitaire de Nice, 06000 Nice, France.
  10. Department of Radiology, Archet 2 Hospital, Centre Hospitalier Universitaire de Nice, 06000 Nice, France.
  11. Centre Méditerranéen de Médecine Moléculaire (C3M), Institut de la Santé et de le Recherche Médicale (INSERM) U1065, 06204 Nice, France.
  12. Institute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
  13. Center for Personalized Oncology (DKFZ-HIPO), Deutsches Krebsforschungszentrum (DKFZ), 69120 Heidelberg, Germany.
  14. Université Côte d'Azur, 06000 Nice, France. [email protected].
  15. Team 4, Institute for Research on Cancer and Aging Nice (IRCAN), Institut de la Santé et de le Recherche Médicale (INSERM) U1081/CNRS 7284, 06107 Nice, France. [email protected].
  16. Laboratory of Clinical and Experimental Pathology, Biobank BB-0033-00025, Centre Hospitalier Universitaire de Nice, 06000 Nice, France. [email protected].
  17. FHU OncoAge, Pasteur Hospital, 06000 Nice, France. [email protected].

PMID: 31470674 PMCID: PMC6769455 DOI: 10.3390/cancers11091271

Abstract

Tumor mutational burden (TMB) has emerged as an important potential biomarker for prediction of response to immune-checkpoint inhibitors (ICIs), notably in non-small cell lung cancer (NSCLC). However, its in-house assessment in routine clinical practice is currently challenging and validation is urgently needed. We have analyzed sixty NSCLC and thirty-six melanoma patients with ICI treatment, using the FoundationOne test (FO) in addition to in-house testing using the Oncomine TML (OTML) panel and evaluated the durable clinical benefit (DCB), defined by >6 months without progressive disease. Comparison of TMB values obtained by both tests demonstrated a high correlation in NSCLC (

Keywords: FoundationOne assay; Oncomine TML assay; immunotherapy; lung cancer; melanoma; tumor mutational burden

Conflict of interest statement

Simon Heeke has received honoraria from Qiagen. Michel Poudenx has received honoraria from Roche, BMS, MSD and Pfizer and has been an investigator for Novartis and MSD. Thierry Passeron has received h

References

  1. J Thorac Oncol. 2019 Nov;14(11):1935-1947 - PubMed
  2. Eur J Cancer. 2009 Jan;45(2):228-47 - PubMed
  3. J Immunother Cancer. 2016 Aug 16;4:48 - PubMed
  4. Forensic Sci Int Genet. 2018 May;34:257-264 - PubMed
  5. Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):E10119-E10126 - PubMed
  6. Science. 2015 Apr 3;348(6230):124-8 - PubMed
  7. Nat Rev Clin Oncol. 2019 Jun;16(6):341-355 - PubMed
  8. Oncotarget. 2015 Oct 27;6(33):34221-7 - PubMed
  9. Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7769-E7777 - PubMed
  10. J Clin Oncol. 2019 Apr 20;37(12):992-1000 - PubMed
  11. Transl Lung Cancer Res. 2018 Dec;7(6):631-638 - PubMed
  12. J Thorac Oncol. 2018 Mar;13(3):447-453 - PubMed
  13. Nat Commun. 2017 Nov 23;8(1):1738 - PubMed
  14. N Engl J Med. 2015 Jan 22;372(4):320-30 - PubMed
  15. Transl Lung Cancer Res. 2018 Dec;7(6):703-715 - PubMed
  16. Cell. 2016 Mar 24;165(1):35-44 - PubMed
  17. Genome Med. 2017 Apr 19;9(1):34 - PubMed
  18. Int J Cancer. 2019 May 1;144(9):2303-2312 - PubMed
  19. Hum Mutat. 2015 Sep;36(9):903-14 - PubMed
  20. Mod Pathol. 2016 Dec;29(12):1552-1564 - PubMed
  21. Ann Oncol. 2019 Sep 1;30(9):1448-1459 - PubMed
  22. Clin Cancer Res. 2018 Jan 15;24(2):407-419 - PubMed
  23. N Engl J Med. 2018 May 31;378(22):2093-2104 - PubMed
  24. Cancer Cell. 2018 May 14;33(5):843-852.e4 - PubMed
  25. Ann Oncol. 2019 Jan 1;30(1):44-56 - PubMed
  26. J Immunother Cancer. 2019 Jul 12;7(1):180 - PubMed
  27. N Engl J Med. 2018 May 31;378(22):2078-2092 - PubMed
  28. J Immunother Cancer. 2019 Aug 6;7(1):206 - PubMed
  29. Front Oncol. 2018 Jul 18;8:270 - PubMed
  30. J Clin Oncol. 2018 Mar 1;36(7):633-641 - PubMed
  31. Transl Lung Cancer Res. 2018 Dec;7(6):616-630 - PubMed
  32. Ann Oncol. 2019 Sep 1;30(9):1496-1506 - PubMed
  33. N Engl J Med. 2017 Jun 22;376(25):2415-2426 - PubMed
  34. Mol Cancer Ther. 2017 Nov;16(11):2598-2608 - PubMed
  35. Cancer Genet. 2015 Sep;208(9):415-27 - PubMed
  36. Nat Genet. 2019 Feb;51(2):202-206 - PubMed
  37. Ann Oncol. 2018 Jan 1;29(1):193-199 - PubMed
  38. JAMA Oncol. 2016 Jan;2(1):46-54 - PubMed
  39. Biomed Res. 2018;39(3):159-167 - PubMed

Publication Types

Grant support